We screened the English-language literature for longitudinal studies reporting the association between baseline CPC/EPC levels, future cardiovascular events, and death. We retrieved 28 studies, 21 of which contained poolable data and entered the meta-analysis, for a total of 4155 patients, mostly with a high baseline cardiovascular risk. Sixty percent of the studies met at least 11 of 16 items of quality assessment. Overall, reduced CPC/EPC levels were associated with a ≈2-fold increased risk of future cardiovascular events and cardiovascular death. The most predictive phenotype was CD34 + CD133 + : low versus high levels predicted cardiovascular events, restenosis after endovascular intervention, cardiovascular death, and all-cause mortality. Heterogeneity among studies and according to the CPC/EPC phenotype was generally high. Excluding studies for which the risk estimate had to be extrapolated or limiting the analyses to higher quality studies still indicated a significant risk for future cardiovascular events and death in patients with low versus high progenitor cell counts. 
P rediction of future cardiovascular events (CVEs) and death by combinations of traditional risk factors yields inaccurate risk estimates, despite advancements in statistical methods and modeling. 1 As a significant proportion of CVE occurs in subjects stratified into low-intermediate risk categories, the sake for cardiovascular risk biomarkers has attracted great interest. 2, 3 An ideal cardiovascular risk biomarker should be biologically related to disease pathophysiology, easily measurable, associated with prevalent and incident cardiovascular disease (CVD) in different populations, able to improve risk stratification, routinely available in clinical practice, and able to drive clinical decisions. 3, 4 Editorial, see p 1863
Circulating progenitor cells (CPCs) are immature bone marrow (BM)-derived cells, mostly of hematopoietic origin, which have been associated with several aspects of CVDs, from diagnosis to therapy. 5 In clinical studies, CPCs are generally defined by flow cytometry based on the surface expression of the hematopoietic stem cell markers CD34 and CD133. CPCs include phenotypes with vascular endothelial specification, usually called endothelial progenitor cells (EPCs). EPCs account for ≤15% of CPCs and are characterized by the coexpression of endothelial markers (mostly the type 2 vascular endothelial growth factor receptor KDR). 5, 6 In animal models, BM-derived progenitor cells contribute to cardiovascular homeostasis by stimulating endothelial repair and angiogenesis through physical integration into the vasculature and paracrine activity. 7 In humans, the levels of circulating CPCs and EPCs are reduced in the presence of classical cardiovascular risk factors and established CVD, such as atherosclerosis in the coronary, peripheral, and cerebrovascular district. 8 Such reduction represents a putative mechanism of impaired vascular homeostasis and a risk factor for future CVEs. In turn, acute CVEs with ischemia (eg, myocardial infarction or stroke) trigger mobilization of CPCs/EPCs from the BM to peripheral blood, 9 possibly as an attempt to provide regenerative cells on request. Failure to do so, is associated with a poorer prognosis. 5 death has never been formally reviewed. Herein, we report the results of a meta-analysis of studies on the association between baseline progenitor cell levels and CVE or death. This overview of available data provides a state-of-the art and critical information to devise future studies assessing the prognostic capacity of CPCs/EPCs.
Methods

Search for Eligible Papers and Inclusion Criteria
We screened the literature for prospective observational studies reporting occurrence of CVEs among patients whose levels of CPCs/EPCs were determined at baseline. Studies using enumeration of cultured endothelial colony-forming cells, often referred to as early EPCs, circulating angiogenic cells, or proangiogenic cells, were also considered. Eligible studies had to be reported in the English literature from 1997 to end of February 2016 and could include either patients undergoing coronary angiography for suspected coronary artery disease or acute coronary syndrome, or patients admitted for stroke, or patients without acute events but with cardiovascular risk factors. Eligible outcomes were (1) CVE (defined as myocardial infarction, percutaneous or surgical coronary revascularization, any acute coronary syndrome, heart failure, stroke, uncontrolled arrhythmia, and cardiovascular death), (2) cardiovascular death, (3) death from any cause, (4) restenosis (defined as intrastent luminal loss or stenosis progression accessed by angiography), and (5) revascularization. We did not exclude a priori any study on the basis of methodological standards, sample size, and duration of follow-up. We searched the MEDLINE database via PubMed up to February 29, 2016 , using the following search terms: (progenitor cells or CD34 + cells or stem cells) and (cardiovascular events or myocardial infarction or stroke or angina or tia or failure or hospitalization or restenosis or death or mortality) and (follow-up or followed-up or incident or incidence). This strategy was complemented by hand searching in the reference lists of retrieved articles and contact with authors. As 2 of the authors (A.A. and G.P.F.) of the present article are also authors of potentially eligible studies, eligibility and risk of bias for such studies were assessed independently by an author with no secondary interest (M.R.), as recommended by the Cochrane Collaboration guidelines. 11 We identified 695 studies. One duplicate and was excluded. Of the remaining studies, 666 were irrelevant to this review and were excluded on the basis of their titles and abstracts. Of the remaining, 7 studies were considered only for descriptive purpose because of missing data, and 21 were included in meta-analysis, for a total of 4155 patients (Figure 1) 
Extraction of Data
We followed the Meta-analysis of Observational Studies in Epidemiology guidelines for performing and reporting results of observational studies. 12 Two reviewers (M.R. and G.P.F.) independently extracted data from eligible articles (n=28) using a predefined coding protocol. Individual item disagreement between the 2 reviewers was resolved by consensus or consultation with a third author (A.A.). We extracted information on year of publication, number of patients at baseline, country, their mean age and percentage of men, the baseline prevalence of diabetes mellitus, hypertension, dyslipidemia, chronic kidney disease, smoke habit, coronary artery disease (proportion with previous coronary events), and the use of cardiovascular medications such as statins or blockers of the renin angiotensin aldosterone system. We collected data on the phenotypic characteristics and baseline levels of CPCs/EPCs, defined as low or high according to receiver operating characteristics curve cut-off, median value, or in relation to their subdivision into tertiles or quintiles. We extracted the reported relative risk, odds ratio or hazard ratio, and 95% confidence intervals from each study. For articles reporting multiple risk measures, we extracted risk measures for the prespecified outcomes with the largest number of adjustment variables. When available, we checked the major adverse cardiovascular event (MACE) breakdown to detect any significant imbalance in its composition. Studies wherein MACE contained a small percentage of hard events (myocardial infarction and stroke) were considered only for more specific outcomes (eg, revascularization).
Quality of Study Reporting
We evaluated the quality of individual study reports according to the Recommendation for MARKER Prognostic Studies (REMARK) guidelines for prognostic biomarker studies. 13 We extracted details of 16 items related to the purpose of studies, population description, biomarker measurement, confounders, outcomes, and analytic choice. Definitions of each item are given in Online Table I .
Statistical Analysis
We compared the effect of low versus high level of CPCs/EPCs on all prespecified outcomes. The reported comparisons included risk estimates onto a standard scale (ie, per 1 SD, per tertile, or per quintile), according to receiver operating characteristics curve cut-off, or per unit of change in cell count. To allow the comparison on a same scale, we standardized the risk expressed per unit of change using the attributable risk approach (Online Table II ). The relative risk estimates of each study and their corresponding SE were transformed to their natural logarithms to normalize distributions. Because of heterogeneity among studies, we used the random-effect meta-analysis using the inverse variance method. In this approach, the weight given to each study is the inverse of the variance of the effect estimate. In general, the larger studies (smaller SE) are given more weight than smaller studies (larger SE), leading to a reduction of the imprecision of pooled effect estimate. However, for comparison, we also report summary statistics obtained using the fixed-effect model, as suggested by Sterne et al. 14 For each outcome, we performed an overall meta-analysis and ≤5 subgroups analysis: (1) considering only studies wherein patients without acute CVEs were enrolled; (2) considering only studies reporting adjusted risk estimates onto a standard scale of effect; (3) considering only studies wherein patients with acute CVEs were enrolled; (4) considering only higher quality studies, defined as having a REMARK score above the median value; (5) 
Results
Overall Characteristics of Included Studies
The meta-analysis included 21 studies, for a total of 4155 patients (average patients per study=198; median [interquartile range]=154 [121-215]). [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] Characteristics of studies included from meta-analysis are given in the Table. The most important reason whereby studies initially retrieved were finally excluded from meta-analysis was the lack of a poolable risk estimate and impossibility to calculate such estimate from the data provided (Online Table III ). Pooled cumulative clinical characteristics of the metaanalyzed patient population are reported in Online Table IV . Four of the 21 studies (n=512 patients, 12.8% of the total population) were conducted in patients with acute coronary syndrome, acute myocardial infarction, or stroke. 20, 25, 27, 34 For the remainders, the underlying disease or condition was elective percutaneous intervention in 7 of 17 studies (n=795 patients; 19.1%), [17] [18] [19] 22, 29, 31, 33 elective coronary angiography for suspected coronary artery disease in 2 of 17 (n=1412 patients; 34.0%), 28, 32 end-stage renal disease in 4 of 17 studies (n=705 patients; 17.0%), 23, 24, 26, 35 chronic heart failure in 1 of 17 studies (n=156 patients; 3.8%), 16 and aortic stenosis in 1 of 17 study (n=261 patients; 6.3%). 35 One study included patients with and without chronic CVD at baseline, 21 and 1 study included both healthy subjects and patients with chronic or acute CVD. 30 Five of 21 studies considered multiple CPCs/EPCs phenotypes at the same time. Phenotypes most frequently used were CD34 + CPCs (6 studies) and CD34 + KDR + EPCs (12 studies). The outcome most commonly considered was the occurrence of future CVEs (16 studies).
Quality of Included Studies
According to a 16-item evaluation, modified from the REMARK guidelines to fit the purpose of this meta-analysis, 13 the median (interquartile range) score was 10 (9-12). Studies had a good quality (>50% of studies) for the following items: prespecified hypothesis, setting, inclusion/exclusion criteria, number of patients at each stage, details on manufacturers and assays for CPCs/EPCs, confounders, hierarchy of outcomes, univariate estimate and adjustment, rationale for group comparisons. Vice versa, quality was overall poor (<50% of studies) for rationale for sample size, description of sample handling, end point validation and masking, handling of missing values (Online Figure I) .
Cardiovascular Events
Two studies reporting on CVE were excluded from this analysis because the MACE breakdown indicated an excessive contamination with nonhard events. 16, 27 The analysis was first conducted for each single-cell phenotype, and then summary statistics for all phenotypes were pooled together. + KDR + cells. The latter showed significant heterogeneity among studies in the association with future CVEs. When phenotype-specific risk estimates were pooled together, the overall risk ratio indicated that a low CPCs/EPCs count was associated with a significant 97% higher risk of future CVEs (Figure 2 ).
When the analysis was repeated excluding studies on patients with acute CVD, who have the highest risk for future events, the overall statistics was lower as expected but still significant (RR, 1.71 [1.16-2.52]). When the analysis excluded studies wherein the risk estimate had to be calculated, the overall statistics was higher (RR, 2.52 [1.56-4.06]) and highly significant. Limiting the analysis to studies with a REMARK score >10 yielded a risk ratio of 1.99 (1.25-3.16; Online Figure IIA ). Such studies also had a more homogeneous definition of the composite cardiovascular outcome, with at least 50% composed by hard end points.
According to the fixed-effect model, the risk ratio would be significant for CD34 + 
Cardiovascular and All-Cause Mortality
Four studies reported cardiovascular death in relation to baseline CPCs/EPCs. Altogether, they show an association between low versus high cell count and the risk for future cardiovascular death, yielding a pooled risk ratio of 1.87 (95% CI, 1.15-3.02). The corresponding risk ratio according to the fixed-effect model was 1.45 (1.22-1.72). However, multiple studies were available only for CD34 + KDR + cells (n=3), and their association with cardiovascular death was highly heterogeneous, yielding a nonsignificant pooled risk ratio ( Figure 3A) .
Data on all-cause mortality were available for most phenotypes. The pooled risk ratio of future death in patients with low versus high cell count was statistically significant for CD34 + . Some EPC phenotypes showed paradoxical opposite trend associations with future death from any cause, and a large heterogeneity among studies was found. As a result, the overall summary statistics for all phenotypes was marginally significant with the random-effect model ( Figure 3B ). According to the fixed-effect model, the pooled risk ratio for all phenotypes would be 1.37 (1.23-1.52; P<0.001). When the random-effect model analysis excluded studies wherein the risk estimate had to be calculated, the overall statistics was 
Restenosis and Revascularization
A few studies reported the risk of restenosis after percutaneous intervention and the need for future revascularization in patients with baseline acute or chronic CVD. The association between low versus high CPCs/EPCs levels and restenosis was highly variable according the cellular phenotype, ranging from a significant protection for low CD34 + cells to a significant harm for low CD34 + CD133 + KDR + cells or colony-forming cells. The overall statistics showed a trend increased risk of future restenosis in patients with low versus high CPCs/ EPCs, with high and significant heterogeneity ( Figure 4A ). Figure IIC) . According to the fixed-effect model, the risk of restenosis associated with a low CPC/EPC cell count would be 2.97 (2.77-3.17). Data on the risk for future revascularization were available only for 3 phenotypes: there was a nonsignificant trend association of reduced risk in patients with low CPCs/EPCs, but heterogeneity was high and statistically significant ( Figure 4B ). Excluding studies conducted in acute CVD patients or studies for which the risk estimate had to be calculated did not change the results using the random-effect model (Online Figure IID) although it yielded a significant risk ratio using the fixed-effect model (RR, 1.21 [1.02-1.43]).
Metaregression Analysis
A metaregression was conducted to detect whether any overall characteristic of study populations consistently modulated the risk estimate. As robustness of metaregression relies on the number of studies included, we only analyzed the risk ratio for the most commonly used progenitor cell phenotype (CD34 + KDR + EPCs) and the most common outcome (CVE). With the random-effect model, the log of risk ratio was significantly associated with the percentage of male patients (direct correlation, P=0.002), the percentage of patients with a previous acute myocardial infarction (direct correlation, P=0.002), and with the percentage of patients on statin (inverse association, P<0.0001; Figure 5 ). No statistically significant outlier was detected in this metaregression.
Excluded Studies
Excluded studies reported data on the relation between CPC/ EPC levels and functional outcome after acute myocardial infarction or stroke. Four studies were conducted on a total of n=309 patients with acute myocardial infarction, overall showing that high CD34 + /CD133 + CPCs predicted improvements in regional or global left ventricular function, [37] [38] [39] and in coronary flow reserve. 40 One study found that mobilization of EPCs during acute ischemia was significantly lower in patients who developed restenosis, 41 whereas a small study in patients with stable angina showed that EPC levels directly correlated with the degree of restenosis. 42 In 1 study conducted in patients with acute ischemic stroke, a low number of baseline EPCs predicted worse functional outcomes after 6 months. 43 
Biases
The number of studies available for which a given CPC/EPC phenotype was assessed in relation to a given outcome was limited. In funnel plots showing all phenotypes simultaneously (Online Figure III) , there is a suggestion of missing studies on the bottom left-hand side of the plot. Because most of this area contains regions of high significance, publication bias is unlikely to be the underlying cause of asymmetry. Heterogeneity likely arose from selective outcome and analysis reporting, and poor quality of some studies.
14
Discussion
This is the first systematic meta-analysis reporting pooled data on the association between levels of CPCs, cardiovascular outcomes, n.a n.a. . Such cell populations are mostly of hematopoietic origin, whereas EPCs, despite their vascular specification, were less consistently associated with the outcome. This discrepancy was noted previously and has different potential explanations. 44 First, circulating CPCs better reflect the BM status than EPCs. 45 Second, KDR + EPCs are rarer than CPCs, show + cells using various modifications of the International Society for Hematotherapy and Graft Engineering (ISHAGE) protocol 46 is routinely available in most hospital laboratories and already used in hematology clinical practice. Therefore, the CD34 + CPC phenotype is candidate to become a clinical-grade biomarker of cardiovascular risk.
Despite preclinical studies offer mechanistic interpretations for the link between low CPC and adverse outcomes, 7 these remain largely speculative. As hematopoietic progenitor cells outperformed EPCs' prognostic power and predicted all-cause mortality in addition to CVE, other, nonvascular, mechanisms may link stem/progenitor cell defects to adverse outcomes. For instance, circulating CPCs reflect the status of the BM, 45 which is typically affected in syndromes characterized by premature death. 47 Therefore, we speculate that reduced CPCs may generally reflect biological aging.
Some studies evaluating the prognostic capacity of CPCs/ EPCs had to be excluded from the meta-analysis because not reporting risk measures. Nonetheless, their main message is that low progenitor cell levels are associated with poor functional outcomes after myocardial infarction or stroke, thereby lending support to the core finding of this meta-analysis.
Two studies in the literature show that, in addition to being associated with a significant risk of future CVD, the measure of circulating progenitors improves risk stratification beyond traditional assessment, as determined by the net reclassification improvement and the integrated discrimination improvement. 28, 48 This information further supports to the clinical utility of measuring CPCs.
Limitations of this meta-analysis need to be acknowledged. Although the possibility to pool data from different cohorts and different phenotypes has been demonstrated, 28, 48 the meaning of pooling risk ratios from all phenotype is unclear. Quality of studies was low for some of the items identified by the REMARK guidelines. 13 Studies were highly heterogeneous in terms of setting, patient population, underlying clinical condition, outcome definition, duration of follow-up, and progenitor cell phenotype. In the presence of large heterogeneity, the random-effect model is preferred, but analyzing eventual differences with the fixed-effect model may be important.
14 Results of the random-and fixed-effect model were similar, suggesting a limited impact of heterogeneity on the overall message of the study. Furthermore, limiting the analysis to higher quality studies yielded a significant risk of adverse outcomes associated with low progenitor cells. Nonetheless, differences among studies translated into a statistically significant heterogeneity of the risk estimate. This was most evident for restenosis and revascularization. The association between low CPCs/EPCs and reduced risk for future revascularization is counterintuitive. Methodologically, differences in the clinical setting (acute versus chronic CVD) and in progenitor cell phenotype may account for this discrepancy. Biologically, reduction of vasculoprotective cells may prevent successful revascularization, by inducing a more severe and occlusive atherosclerosis, less amenable to surgical or endovascular intervention. Furthermore, in 7 of 21 studies, the risk ratio reported in the original article had to be re-elaborated or extrapolated from other statistics to be entered in the meta-analysis. Excluding such studies increased statistical significance and reduced heterogeneity. All meta-analyzed studies included patients at a high cardiovascular risk at baseline, mostly in secondary prevention, and 5 studies enrolled only patients with acute CVD, who have the highest short-term cardiovascular risk. As the CPC/EPC enumeration is usually by guest on January 7, 2018 http://circres.ahajournals.org/ performed on fresh samples, to yield a sufficient statistical power in the analysis of event-free survival with relatively small sample size and short follow-up, high-risk patients need to be enrolled. Because biomarkers perform better in high-risk than in low-risk populations, 3, 49 whether the levels of CPCs/EPCs provide prognostic information also in the general population remains unclear. Some observations suggest that the prognostic power of CPCs/EPCs is proportional to the baseline cardiovascular risk. First, the exclusion of studies that enrolled only patients with acute events lowered the risk ratio for future CVE associated with low progenitor cells, which however remained statistically significant. Second, the metaregression showed that the risk ratio was higher in studies wherein patients were more often men, had a higher prevalence of baseline CVD, and were less frequently on statins. Metaregression should be considered with caution, as it was performed only for CD34 + KDR + cells versus CVE because validity, outlier, and influence analysis strongly relies on the number of studies included.
In conclusion, this meta-analysis shows that a reduction in the levels of circulating cells provided with vasculoregenerative capacity in preclinical models represents a risk factor for adverse cardiovascular outcomes and death. Future longitudinal studies on the prognostic capacity of CPC levels should be multicentric, use standardized assessment of CD34 + cells on both fresh and frozen samples, conducted on lower risk populations, and have longer follow-up. The final challenge will be an assessment of whether the measure of CPCs can guide clinical decisions.
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What New Information Does This Article Contribute?
• A formal meta-analysis of longitudinal studies assessing the prognostic impact of CPCs.
• Low versus high CPC levels independently predict cardiovascular and all-cause mortality and future cardiovascular events.
• High heterogeneity among studies limits the generalizability of the findings, but CPCs could be a potential biomarker for assessing cardiovascular disease.
Several studies have evaluated the prognostic impact of having a reduced level of CPCs at baseline in terms of cardiovascular risk and mortality, but these vary widely in patients' characteristics, underlining conditions, follow-up durations, end points, and types of CPCs analyzed. Our meta-analysis shows that a reduction in the levels of circulating cells with putative cardiovascular regenerative properties represents a risk factor for adverse cardiovascular outcomes and death. The extent and significance of the increased risk associated with reduced CPC levels deserve additional mechanistic investigation, particularly those relating to bone marrow alterations leading to CPC reduction. Clinically, CPC levels could potentially be a new biomarker of cardiovascular risk and biological aging. Ace-i/ARB (%) 50.5
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Online Figure II . Subanalyses. For cardiovascular events (a), all-cause mortality (b), restenosis (c), and revascularization (d), up to 5 subanalyses are reported. Subanalysis 1 was performed excluding studies conducted only in patients with acute CVD. Subanalysis 2 was performed excluding studies for which the risk estimate had to be calculated (see Online table II) . Subanalysis 3 was performed only including studies conducted only in patients with acute CVD. Subanalysis 4 was performed only with higher quality studies (>10 REMARK items). Subanalysis 5 was performed only with studies having a homogeneous definition of the composite cardiovascular endpoint (>50% hard events). 
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